Advanced

Gene expression profiling in MDS and AML: potential and future avenues.

Theilgaard-Moench, Kim LU ; Boultwood, J; Ferrari, S; Giannopoulos, K; Hernandez-Rivas, J M; Kohlmann, A; Morgan, M; Porse, B; Tagliafico, E and Zwaan, C M, et al. (2011) In Leukemia 25(6). p.909-920
Abstract
Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an attempt to better reflect disease biology. However, in many MDS/AML patients no genetic aberrations have been identified yet, and even within some cytogenetically well-defined subclasses there is considerable clinical heterogeneity. Recent advances in genomics technologies such as gene expression profiling (GEP) provide powerful tools to further characterize myeloid malignancies at the molecular level, with the goal to refine the MDS/AML classification system, incorporating as yet unknown molecular genetic and epigenetic pathomechanisms, which are likely reflected by... (More)
Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an attempt to better reflect disease biology. However, in many MDS/AML patients no genetic aberrations have been identified yet, and even within some cytogenetically well-defined subclasses there is considerable clinical heterogeneity. Recent advances in genomics technologies such as gene expression profiling (GEP) provide powerful tools to further characterize myeloid malignancies at the molecular level, with the goal to refine the MDS/AML classification system, incorporating as yet unknown molecular genetic and epigenetic pathomechanisms, which are likely reflected by aberrant gene expression patterns. In this study, we provide a comprehensive review on how GEP has contributed to a refined molecular taxonomy of MDS and AML with regard to diagnosis, prediction of clinical outcome, discovery of novel subclasses and identification of novel therapeutic targets and novel drugs. As many challenges remain ahead, we discuss the pitfalls of this technology and its potential including future integrative studies with other genomics technologies, which will continue to improve our understanding of malignant transformation in myeloid malignancies and thereby contribute to individualized risk-adapted treatment strategies for MDS and AML patients.Leukemia advance online publication, 29 March 2011; doi:10.1038/leu.2011.48. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
gene expression profiling, acute myeloid leukemia, myelodysplastic syndrome, microarray, connectivity MAP, drug discovery
in
Leukemia
volume
25
issue
6
pages
909 - 920
publisher
Nature Publishing Group
external identifiers
  • wos:000291386900003
  • pmid:21445077
  • scopus:79958097977
ISSN
1476-5551
DOI
10.1038/leu.2011.48
language
English
LU publication?
yes
id
6b23654c-9ccf-4cfb-b503-355c45c5115b (old id 1883358)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21445077?dopt=Abstract
date added to LUP
2012-01-19 11:53:45
date last changed
2017-11-19 03:03:05
@article{6b23654c-9ccf-4cfb-b503-355c45c5115b,
  abstract     = {Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an attempt to better reflect disease biology. However, in many MDS/AML patients no genetic aberrations have been identified yet, and even within some cytogenetically well-defined subclasses there is considerable clinical heterogeneity. Recent advances in genomics technologies such as gene expression profiling (GEP) provide powerful tools to further characterize myeloid malignancies at the molecular level, with the goal to refine the MDS/AML classification system, incorporating as yet unknown molecular genetic and epigenetic pathomechanisms, which are likely reflected by aberrant gene expression patterns. In this study, we provide a comprehensive review on how GEP has contributed to a refined molecular taxonomy of MDS and AML with regard to diagnosis, prediction of clinical outcome, discovery of novel subclasses and identification of novel therapeutic targets and novel drugs. As many challenges remain ahead, we discuss the pitfalls of this technology and its potential including future integrative studies with other genomics technologies, which will continue to improve our understanding of malignant transformation in myeloid malignancies and thereby contribute to individualized risk-adapted treatment strategies for MDS and AML patients.Leukemia advance online publication, 29 March 2011; doi:10.1038/leu.2011.48.},
  author       = {Theilgaard-Moench, Kim and Boultwood, J and Ferrari, S and Giannopoulos, K and Hernandez-Rivas, J M and Kohlmann, A and Morgan, M and Porse, B and Tagliafico, E and Zwaan, C M and Wainscoat, J and Van den Heuvel-Eibrink, M M and Mills, K and Bullinger, L},
  issn         = {1476-5551},
  keyword      = {gene expression profiling,acute myeloid leukemia,myelodysplastic syndrome,microarray,connectivity MAP,drug discovery},
  language     = {eng},
  number       = {6},
  pages        = {909--920},
  publisher    = {Nature Publishing Group},
  series       = {Leukemia},
  title        = {Gene expression profiling in MDS and AML: potential and future avenues.},
  url          = {http://dx.doi.org/10.1038/leu.2011.48},
  volume       = {25},
  year         = {2011},
}